Cytonics

[Closed for Investment] Cytonics Corporation, with a pre-money valuation of $46.7 million, is raising funds on SeedInvest through Reg A+ crowdfunding. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system concentrating A2M from patients’ blood to treat their own damaged joints. Cytonics Corporation was founded by Gaetano Scuderi and has raised over $15 million in previous rounds of financing. The current round of funding has a minimum raise of $1,500,000 and a maximum raise of $19,000,000, and the funds will be used for GMP production of CYT-108, GLP pre-clinical animal study, Phase 1 human clinical trial, and Phase 2 human clinical trial. Cytonics Corporation has already initiated a pilot pre-clinical study for its lead drug candidate CYT-108 in 2019. It is a biologic therapy modeled after the naturally occurring A2M molecule found in the blood.

Expand

Investment Overview

Raised this Round: Raised: $4,667,638

Deal Terms

Total Commitments ($USD)

Platform
SeedInvest
Start Date
07/10/2020
Close Date
04/30/2021
Min. Goal
$1,500,000
Max. Goal
$19,000,000
Min. Investment

$1,000

Security Type

Equity - Preferred

Series

Series C

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$2.00

Pre-Money Valuation

$46,701,000

Company & Team

Company

Year Founded
2006
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B2C
Margin
Medium
Capital Intensity
High
Location
Jupiter, Florida
Business Type
Growth
Company Website
Visit Website

Team

Employees
8
Prior Founder Exits?
No
Founder Name
Gaetano Scuderi
Title
Chairman of the Board

Financials

 Revenue
$365,169
 Monthly Burn
$81,410
 Runway
6.6 months

Balance Sheet

Cash and Cash Equivalents

$537,592

Investment Securities

$0

Total Investments

$0

Accounts and Notes Receivable

$18,417

Loans

$0

Property, Plant and Equipment (PP&E)

$0

Property and Equipment

$0

Total Assets

$1,056,608

Accounts Payable & Accrued Liabilities

$157,633

Policy Liabilities and Accruals

$0

Deposits

$0

Long Term Debt

$1,061,904

Total Liabilities

$1,219,537

Total Stockholders' Equity

$-162,929

Total Liabilities and Equity

$1,056,608

Statement of Comprehensive Income Information

Total Revenues

$365,169

Total Interest Income

$0

Costs & Expenses Applicable to Rev

$1,119,923

Total Interest Expenses

$0

Depreciation and Amortization

$28,823

Net Income

$-976,922

Earnings Per Share - Basic

$-0.10

Earnings Per Share - Diluted

$-0.10

Auditor: D. Brooks and Associates CPA's, P.A.
Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
08/25/2024 StartEngine $66,557,294 $938,436 Equity - Preferred Funded RegCF
05/28/2024 StartEngine $65,792,080 $3,626,034 Equity - Preferred Funded RegCF
03/31/2023 Dealmaker Securities $58,915,995 $1,695,868 Equity - Preferred Funded RegCF
10/14/2022 SeedInvest $58,915,996 $2,633,766 Equity - Preferred Funded RegCF / RegD 506(c)
04/30/2021 SeedInvest $46,701,000 $4,667,638 Equity - Preferred Funded RegA+
05/18/2019 SeedInvest $32,400,000 $494,344 Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Cytonics Corporation on SeedInvest
Platform: SeedInvest
Security Type: Equity - Preferred
Valuation: $46,701,000
Price per Share: $2.00

Follow company

Follow Cytonics Corporation on SeedInvest

Buy Cytonics's Deal Report

Warning: according to the close date for this deal, Cytonics may no longer be accepting investments.

Cytonics Deal Report

Get Kingscrowd's comprehensive report on Cytonics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Cytonics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Cytonics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge